Tempest Therapeutics Struggles: A Financial Storm Brews Amidst Mounting Losses and Development Hurdles
Company Announcements

Tempest Therapeutics Struggles: A Financial Storm Brews Amidst Mounting Losses and Development Hurdles

Tempest Therapeutics, Inc. (TPST) has disclosed a new risk, in the Innovation / R&D category.

Tempest Therapeutics, Inc., a clinical-stage biotechnology firm with a brief operational history, faces substantial risk in its product development endeavors. The company’s activities have predominantly focused on foundational and developmental aspects, such as staffing, capital fundraising, and research for their product candidates, without generating any revenue through product sales. With net losses amounting to $29.5 million and $35.7 million in the last two consecutive years and an accumulated deficit of $165.3 million, Tempest Therapeutics anticipates continuing significant expenses and losses. These financial challenges pose a serious risk to the company’s ability to sustain its development programs, potentially necessitating delays, reductions, or the termination of certain projects.

The average TPST stock price target is $20.75, implying 451.86% upside potential.

To learn more about Tempest Therapeutics, Inc.’s risk factors, click here.

Related Articles
TheFlyTempest Therapeutics files $300M mixed securities shelf
TheFlyTempest Therapeutics unveils new survival data for amezalpat
GlobeNewswireTempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!